Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$10.74
Price+9.70%
$0.95
$737.126m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$364k
-
1y CAGR-
3y CAGR-
5y CAGR-$142.295m
-
1y CAGR-
3y CAGR-
5y CAGR-$2.04
-
1y CAGR-
3y CAGR-
5y CAGR$345.236m
$382.002m
Assets$36.766m
Liabilities$1.755m
Debt0.5%
-
Debt to EBITDA-$127.003m
-
1y CAGR-
3y CAGR-
5y CAGR